WAYNE, N.J. and EMERYVILLE, Calif., May 16 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced more than 40 data presentations at the 2008 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the potential for Nexavar(R) (sorafenib) tablets in multiple tumor types as a single agent or in combination with other agents.
"Data at ASCO will expand upon and support the proven efficacy and
tolerability of Nexavar in liver cancer and advanced kidney cancer and
provide new insight into the potential of Nexavar in additional types of
cancer," said Henry Fuchs, MD, executive vice president and chief medical
officer of Onyx Pharmaceuticals. "Highlights include studies demonstrating
that Nexavar extends life for Asian patients with liver cancer; provides an
effective, well-tolerated option for elderly patients with advanced kidney
cancer and may provide benefit and warrants further study in heavily
pretreated patients with non-small cell lung cancer."
Nexavar data highlights include:
-- Randomized Phase III trial of sorafenib versus placebo in Asian
patients with advanced hepatocellular carcinoma
-- Ann Lii-Cheng, MD, PhD, department of internal medicine, National
Taiwan University Hospital, Taipei, Taiwan
-- Abstract #4509, oral presentation, Monday, June 02, 2008,
4:30 - 4:45 p.m., E-Hall D2
-- Efficacy and safety of sorafenib in patients with advanced
hepatocellular carcinoma and vascular invasion or extrahepatic spread:
a subanalysis from the SHARP trial
-- Morris Sherman, MD, PhD, associate professor of medic
|SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved